Clinical Trials
During recruitment period
These trials have already begun recruiting volunteers.
RECLAIM
PHASE III
Adults with diabetic foot infections (DFI), the goal of the study is to determine if the experimental drug (contezolid acefosamil and contezolid) has equal efficacy with fewer side effects than an approved drug (linezolid).
Be over 18 years of age, with a diagnosis of diabetes mellitus (Type 1 or 2) and suffer from a diabetic foot infection.
2 months in total (1 month with medication and 1 month of follow-up)
eVOLVE-Lung02
PHASE III
Adults with metastatic non-small cell lung cancer (mNSCLC). It will be studied whether volrustomig (new type of immunotherapy) + chemotherapy works better than pembrolizumab + chemotherapy
Being over 18 years of age with low levels of PD-L1 in their mNSCLC cells.
PSUMMIT Jr
PHASE III
To evaluate the efficacy, pharmacokinetics, safety and immunogenicity of ustekinumab administered subcutaneously in pediatric participants with active juvenile psoriatic arthritis (PSUMMIT Jr)
Pediatric participants aged ≥5 to <18 years with active PsJA
13 months (follow-up up to 17 months)
Bordetella
OBS.
To determine the proportion of Bp infections in adults ≥ 50 years of age with cough. To describe the clinical and epidemiological characteristics and the variables associated with Bp confirmed by laboratory analysis, in cities in Argentina.
People ≥50 years old whose main reason for consultation is cough lasting more than 72 hours and less than 4 weeks.
1 day of sample collection and 2 days of follow-up (at 7 and 30 days)
Debiopharm
PHASE IIa
To evaluate the safety and tolerability of afabicin in the treatment of patients with bone or joint infections (BIO) (septic arthritis, osteomyelitis, prosthetic joint infection [PAI]) due to Staphylococcus aureus (both methicillin-susceptible S. aureus [MSSA]). such as methicillin-resistant S. aureus [MRSA]) and/or coagulase-negative staphylococci (NEC), and compare it with standard treatment (ST).
18 years of age or older with a diagnosis of septic arthritis, osteomyelitis, or prosthetic joint infection
The duration of the treatment period is estimated between 3 and 6 weeks.
TILIA
PHASE III
It is a clinical study investigating a new treatment called tozorakimab for patients hospitalized with viral lung infections. It is being studied whether it can reduce the risk of acute respiratory distress syndrome (ARDS).
To start
These studies already have most of the necessary approvals and will soon begin their recruitment period.
OTAC 012
OBS.
The objective is to determine the Safety and Efficacy of Immunoglobulin
Intravenous Anti-Coronavirus for the Treatment of Adult Outpatients in Early Phases of COVID-19
Clinical risk based on age ≥ 55 years or an adult (age ≥ 18 years) with a immunosuppression condition.
Test positive for SARS-CoV-2
28 days
AJAX
PHASE IIa
Evaluate the Efficacy and Safety of an Asthma Medication
Adult patients with uncontrolled moderate to severe asthma
12 weeks
